Cancers of unknown primary origin

Current perspectives and future therapeutic strategies

Giulia M. Stella, Rebecca Senetta, Adele Cassenti, Margherita Ronco, Paola Cassoni

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes, rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of a clearly detectable primary mass. This kind of disease is referred to as cancer of unknown primary (CUP) origin and accounts for 3-5% of all cancer diagnosis. There is poor consensus on the extent of diagnostic and pathologic evaluations required for these enigmatic cases which still lack effective treatment. Although technology to predict the primary tumour site of origin is improving rapidly, the key issue is concerning the biology which drives early occult metastatic spreading. This review provides the state of the art about clinical and therapeutic management of this malignant syndrome; main interest is addressed to the most recent improvements in CUP molecular biology and pathology, which will lead to successful tailored therapeutic options.

Original languageEnglish
Article number12
JournalJournal of Translational Medicine
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 24 2012

Fingerprint

Tumors
Molecular biology
Pathology
Neoplasms
Therapeutics
Molecular Pathology
Molecular Biology
Technology

Keywords

  • Cancer
  • Invasive growth
  • Metastases
  • Mutations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cancers of unknown primary origin : Current perspectives and future therapeutic strategies. / Stella, Giulia M.; Senetta, Rebecca; Cassenti, Adele; Ronco, Margherita; Cassoni, Paola.

In: Journal of Translational Medicine, Vol. 10, No. 1, 12, 24.01.2012.

Research output: Contribution to journalArticle

Stella, Giulia M. ; Senetta, Rebecca ; Cassenti, Adele ; Ronco, Margherita ; Cassoni, Paola. / Cancers of unknown primary origin : Current perspectives and future therapeutic strategies. In: Journal of Translational Medicine. 2012 ; Vol. 10, No. 1.
@article{ea9ff9dd84f44a68be2e735dfc5f80b7,
title = "Cancers of unknown primary origin: Current perspectives and future therapeutic strategies",
abstract = "It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes, rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of a clearly detectable primary mass. This kind of disease is referred to as cancer of unknown primary (CUP) origin and accounts for 3-5{\%} of all cancer diagnosis. There is poor consensus on the extent of diagnostic and pathologic evaluations required for these enigmatic cases which still lack effective treatment. Although technology to predict the primary tumour site of origin is improving rapidly, the key issue is concerning the biology which drives early occult metastatic spreading. This review provides the state of the art about clinical and therapeutic management of this malignant syndrome; main interest is addressed to the most recent improvements in CUP molecular biology and pathology, which will lead to successful tailored therapeutic options.",
keywords = "Cancer, Invasive growth, Metastases, Mutations",
author = "Stella, {Giulia M.} and Rebecca Senetta and Adele Cassenti and Margherita Ronco and Paola Cassoni",
year = "2012",
month = "1",
day = "24",
doi = "10.1186/1479-5876-10-12",
language = "English",
volume = "10",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Cancers of unknown primary origin

T2 - Current perspectives and future therapeutic strategies

AU - Stella, Giulia M.

AU - Senetta, Rebecca

AU - Cassenti, Adele

AU - Ronco, Margherita

AU - Cassoni, Paola

PY - 2012/1/24

Y1 - 2012/1/24

N2 - It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes, rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of a clearly detectable primary mass. This kind of disease is referred to as cancer of unknown primary (CUP) origin and accounts for 3-5% of all cancer diagnosis. There is poor consensus on the extent of diagnostic and pathologic evaluations required for these enigmatic cases which still lack effective treatment. Although technology to predict the primary tumour site of origin is improving rapidly, the key issue is concerning the biology which drives early occult metastatic spreading. This review provides the state of the art about clinical and therapeutic management of this malignant syndrome; main interest is addressed to the most recent improvements in CUP molecular biology and pathology, which will lead to successful tailored therapeutic options.

AB - It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes, rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of a clearly detectable primary mass. This kind of disease is referred to as cancer of unknown primary (CUP) origin and accounts for 3-5% of all cancer diagnosis. There is poor consensus on the extent of diagnostic and pathologic evaluations required for these enigmatic cases which still lack effective treatment. Although technology to predict the primary tumour site of origin is improving rapidly, the key issue is concerning the biology which drives early occult metastatic spreading. This review provides the state of the art about clinical and therapeutic management of this malignant syndrome; main interest is addressed to the most recent improvements in CUP molecular biology and pathology, which will lead to successful tailored therapeutic options.

KW - Cancer

KW - Invasive growth

KW - Metastases

KW - Mutations

UR - http://www.scopus.com/inward/record.url?scp=84856071488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856071488&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-10-12

DO - 10.1186/1479-5876-10-12

M3 - Article

VL - 10

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 12

ER -